Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.86, $0.12 better than the analyst estimate of $0.74. Revenue for the quarter came in at $385.19 million versus the consensus estimate of $380.6 million.

GUIDANCE:

Integra LifeSciences sees Q4 2022 EPS of $0.87-$0.91, versus the consensus of $0.88. Integra LifeSciences sees Q4 2022 revenue of $391-403 million, versus the consensus of $403.5 million.

Integra LifeSciences sees FY2022 EPS of $3.29-$3.33, versus the consensus of $3.15.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.